Educational Exhibit Abstract No. 408 - Balloon-occluded retrograde transvenous obliteration of gastric varices

Abstract

No. 410 Risk factors for major complications during percutaneous microwave ablation of hepatic tumors E. Dayan, J. Song, E. Kim, R.S. Patel, S.F. Nowakowski, R. A. Lookstein, A.M. Fischman; Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY Purpose: To identify risk factors for development of major complications using percutaneous microwave ablation (MWA) in the treatment of liver tumors. Materials and Methods: Over a 28 month period, 147 patients with unresectable liver tumors (39 women, 108 men; mean age 67) underwent 164 percutaneous CT guided MWA procedures using the Certus 140 2.45GHz gas cooled probe (Neuwave Medical, Madison, WI). A retrospective analysis was performed to review tumor characteristics as well as technical and clinical outcomes. Follow-up consisted of a clinic visit and CT or MRI at 1 month and every 3-4 months thereafter. Chi- square analysis and two sample t-test were performed to identify whether any tumor or patient related variables were associated with development of major complications. Results: A total of 164 tumors were treated (median size 1.8 cm; 0.6-8.2). Tumor size included: o3cm 142/164 (87%), 3- 5cm -20/164 (12%), 45cm 2/164 (1%). Tumor pathology included: 148/164 (90%) hepatocellular carcinoma and 16/164 (10%) liver metastases. Mortality was 0% at 30 and 90 days. Median length of hospital stay was 1 day (range 0-17 days). The most common major complication was pneumothorax requiring chest tube in 7/147 (5%) patients.The second most common major complication was post procedure pulmonary edema requiring intubation in 3/147 (2%) patients. Tumor size, Child- Pugh score, number of ablation sessions, prior hepatic resection and transarterial chemoembolization were not associated with a higher rate of major complications (p40.05). However, a trend is noted of patients who developed one major complication were more likely to develop additional major complications. Conclusion: Percutaneous MWA is a safe method to treat unresectable liver tumors with a low rate of major JVIR ’ Posters and Exhibits S179 P oters nd Exibits